BERGENBIO ASA financials
BERGENBIO ASA
213800TYYFXKYF3V2A23 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | NOK 848.0K | NOK 354.0K |
| Operating expenses | NOK 152.1M | NOK 192.2M |
| Operating profit (EBIT) | -NOK 151.2M | -NOK 191.8M |
| Net finance income / (cost) | NOK 12.0M | NOK 1.4M |
| Finance costs | NOK 4.7M | NOK 12.0M |
| Profit before tax | -NOK 139.3M | -NOK 190.4M |
| Income tax expense | NOK 0 | NOK 0 |
| Profit for the year | -NOK 139.3M | -NOK 190.4M |
| Total comprehensive income | -NOK 140.5M | -NOK 189.2M |
| Per share | ||
| Basic EPS | NOK -3.95 | NOK -0.13 |
| Diluted EPS | NOK -3.95 | NOK -0.13 |
| Cash flow statement | ||
| Net cash from operating activities | -NOK 153.2M | -NOK 225.1M |
| Net cash from investing activities | NOK 3.7M | NOK 3.1M |
| Net cash from financing activities | NOK 129.6M | NOK 224.9M |
| Lease liability payments | NOK 438.0K | NOK 193.0K |
| Net change in cash | -NOK 19.9M | NOK 2.8M |
| Balance sheet | ||
| Total assets | NOK 155.8M | NOK 174.3M |
| Non-current assets | NOK 1.3M | NOK 431.0K |
| Current assets | NOK 154.5M | NOK 173.9M |
| Cash & equivalents | NOK 140.2M | NOK 156.4M |
| Total equity | NOK 122.7M | NOK 127.5M |
| Non-current liabilities | NOK 818.0K | NOK 0 |
| Lease liabilities (non-current) | NOK 818.0K | NOK 0 |
| Current liabilities | NOK 32.3M | NOK 46.9M |
| Derived metrics | ||
| Operating margin | -17834.2% | -54186.2% |
| Net margin | -16424.8% | -53785.6% |
| Return on equity | -113.5% | -149.4% |
| Cash conversion ratio | 1.10× | 1.18× |
| Other reported items | ||
| Additional Paidin Capital | NOK 52.7M | NOK 47.0M |
| Adjustments For Depreciation Expense | NOK 456.0K | NOK 223.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -NOK 14.6M | -NOK 31.8M |
| Adjustments For Interest Income | NOK 3.5M | NOK 3.1M |
| Adjustments For Provisions | -NOK 42.0K | NOK 42.0K |
| Adjustments For Sharebased Payments | NOK 5.7M | NOK 3.1M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -NOK 4.9M | -NOK 1.6M |
| Comprehensive Income Attributable To Noncontrolling Interests | NOK 0 | NOK 0 |
| Comprehensive Income Attributable To Owners of Parent | -NOK 140.5M | -NOK 189.2M |
| Current Provisions | NOK 0 | NOK 42.0K |
| Depreciation Expense | NOK 456.0K | NOK 223.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | NOK 3.7M | NOK 2.8M |
| Equity and Liabilities | NOK 155.8M | NOK 174.3M |
| Finance Income | NOK 16.7M | NOK 13.4M |
| Increase Decrease Through Sharebased Payment Transactions | NOK 5.7M | NOK 3.1M |
| Increase Decrease Through Transactions With Owners | NOK 135.8M | NOK 228.2M |
| Interest Received Classified As Investing Activities | NOK 3.5M | NOK 3.1M |
| Issue of Equity | NOK 153.1M | NOK 262.0M |
| Issued Capital | NOK 39.1M | NOK 268.9M |
| Liabilities | NOK 33.1M | NOK 46.9M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -NOK 1.2M | NOK 1.2M |
| Other Current Assets | NOK 14.4M | NOK 17.5M |
| Other Current Liabilities | NOK 19.4M | NOK 28.2M |
| Other Employee Expense | NOK 5.7M | NOK 3.2M |
| Other Expense By Nature | NOK 111.0M | NOK 136.3M |
| Payments For Share Issue Costs | NOK 8.8M | NOK 37.0M |
| Proceeds From Issuing Shares | NOK 138.9M | NOK 262.0M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | NOK 167.0K | NOK 0 |
| Reduction of Issued Capital | NOK 0 | — |
| Retained Earnings | NOK 22.0M | -NOK 189.2M |
| Share Issue Related Cost | NOK 23.1M | NOK 37.0M |
| Share Premium | NOK 8.9M | NOK 854.0K |
| Trade and Other Current Payables To Trade Suppliers | NOK 12.9M | NOK 18.6M |
| Wages and Salaries | NOK 34.9M | NOK 52.4M |
Every line item above is a fact tagged in BERGENBIO ASA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (NOK), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.